Turn out the Light: 'Switch' Determines Cancer Cell Fate
News May 03, 2013
At the cellular level, wrong decisions can be made right. Cornell engineers with clinicians at Weill Cornell Medical College have discovered that colon cancer stem cells, a particularly malignant population of cancer cells, are able to switch between the decision to proliferate or to remain constant – and this “switch” is controlled by a little-studied molecule called microRNA.
The research, published online May 2 in the journal Cell Stem Cell, was led by senior author Xiling Shen, assistant professor of electrical and computer engineering, with clinician Steven M. Lipkin, associate professor of medicine at Weill Cornell Medical College. The multidisciplinary work involves engineers, biologists and doctors.
Cancer stem cells live in tumors and share characteristics of regular stem cells – they “decide” what to become. In early stage, noninvasive tumors, say the researchers, cancer stem cells are biased toward asymmetric division – meaning the population of cancer stem cells remains constant. But in more malignant, late-stage tumors, these cells tend to promote symmetric division, or fast proliferation, by making identical copies of themselves, which leads to invasion and metastasis, or spread of cancer cells.
MicroRNA, known as a non-coding RNA, is a relatively understudied molecule because unlike regular messenger RNA, it doesn’t make proteins, and therefore, its importance in biological functions has not been well characterized.
“MicroRNA, which is usually thought to be dispensable in normal tissue, has been largely overlooked in its role in determining cancer outcomes,” Shen said.
Using clinically relevant samples from colon cancer patients at NewYork-Presbyterian/Weill Cornell Medical Center who provided permission, the team conducted experiments to determine a link between the presence of a microRNA called miR-34a and tumor size, metastatic potential and chemoresistance in cancer patients.
They discovered that microRNA acts as a sharp on-off switch that controls the mode of division of colon cancer stem cells, symmetric or asymmetric, in a mechanism distinct from protein regulators.
By changing the number of binding sites of microRNA in a given sample, the dynamics of the system can be tuned to be sharp or gradual – lots of microRNA binding sites make the switch very sharp; fewer make the switch more gradual.
By studying how microRNA affects cancer in real patient tumors, the researchers hypothesize that late-stage tumors try to shut down the switching mechanism so that cells are free to produce even more cancer stem cells. This is why therapies that might arise from this discovery would need to be “upstream” of the microRNA binding – that is, it’s better to control the switching at the microRNA level rather than just increasing the population of microRNA later, when the cancer has already spread.
Shen, a trained electrical engineer, confesses a longtime fascination with the concept of how cells make decisions – the classical example being stem cells, which must decide whether and when to differentiate into myriad other types of cells and how to spatially allocate them. But what controls this process? Shen likes to think of cells as circuits – how they are wired determines not only their decision-making prowess, but also how robust those decisions are.
The study, “A MicroRNA miR-34a Regulated Bimodal Switch Targets Notch in Colon Cancer Stem Cells,” was supported by the National Institutes of Health, National Science Foundation, Defense Advanced Research Projects Agency, Cornell Nanobiotechnology Center, Cornell Stem Cell Program and a gift from philanthropist Matthew Bell.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.